Record Details

Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women

ScholarsArchive at Oregon State University

Field Value
Title Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women
Names Atrio, Jessica (creator)
Stanczyk, Frank Z. (creator)
Neely, Michael (creator)
Cherala, Ganesh (creator)
Kovacs, Andrea (creator)
Mishell, Daniel R., Jr. (creator)
Date Issued 2014-01-01 (iso8601)
Note This is the publisher’s final pdf. The published article is copyrighted by Lippincott Williams & Wilkins and can be found at: http://journals.lww.com/jaids/Pages/default.aspx.

This is an open-access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivatives 3.0 License,
where it is permissible to download and share the work provided it is
properly cited. The work cannot be changed in any way or used
commercially.
Abstract OBJECTIVE: Pharmacokinetic interactions exist between combined
oral contraceptives and protease inhibitors (PI). However, such
information is lacking for progestin-only oral contraception. We
sought to define the steady-state pharmacokinetic interaction between
norethindrone (NET) and PI in HIV-infected women.


METHODS AND DESIGN: We conducted an open-label, prospective,
nonrandomized trial to characterize the steady-state pharmacokinetics
of serum NET in HIV-infected women receiving PI compared
with a control group of HIV-infected women receiving other
noninteracting drugs. After 21 days of 0.35 mg of NET ingestion
once daily, serial serum samples were obtained at 0, 1, 2, 3, 4, 6, 8,
12, 24, 48, and 72 hours. The area under the curve between 0 and
72 hours after ingestion was calculated by trapezoidal approximation.


RESULTS: Thirty-five women were enrolled, 2 withdrew. Sixteen
women in the PI group and 17 controls completed the study. NET
half-life and maximum concentration were not significantly different
between the 2 groups. Minimum concentration of NET was significantly
higher in the PI group (P = 0.01). The ratio of the geometric
mean NET area under the curve in the PI group compared with controls
was 1.5 (90% confidence interval: 1.21 to 1.86). NET serum
concentrations were significantly higher in HIV-infected women taking
a PI compared with controls (P = 0.004).


CONCLUSIONS: Coadministration of PI inhibits NET metabolism as
shown by higher serum NET area under the curve levels, a surrogate
marker for therapeutic contraceptive efficacy. This study supports
the increased utilization of progestin-only pills in HIV-infected
women receiving certain PI regimens.
Genre Article
Access Condition http://creativecommons.org/licenses/by-nc-nd/3.0/us/
Topic HIV
Identifier Atrio, J., Stanczyk, F. Z., Neely, M., Cherala, G., Kovacs, A., & Mishell Jr, D. R. (2014). Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes, 65(1), 72-77. doi:10.1097/QAI.0b013e3182a9b3f1

© Western Waters Digital Library - GWLA member projects - Designed by the J. Willard Marriott Library - Hosted by Oregon State University Libraries and Press